Form 4: UTHR CEO Executes Final 10b5-1 Plan Trades

United Therapeutics CEO Martine Rothblatt completed the final transactions under a pre-arranged 10b5-1 trading plan, exercising options and selling common stock.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), executed the final transactions under a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• Over three days (December 17-19, 2025), Rothblatt exercised stock options for a total of 10,000 shares at an exercise price of $120.26 per share.
• Concurrently, Rothblatt sold a total of 10,000 shares of common stock at weighted average prices ranging from $500.52 to $510.8633 per share.
• Following these transactions, Rothblatt directly owns 130 shares of common stock and indirectly owns 639,359 shares through various family trusts and spouse.
• All derivative stock options related to these transactions have been exercised and disposed of.

Sentiment

Score: 6

Explanation: The transactions are part of a pre-arranged 10b5-1 plan, which is a neutral event. The significant profit from option exercise and sale at high prices is positive, but the reduction in direct ownership by the CEO could be seen as slightly negative by some investors, though offset by substantial indirect holdings.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock sales.
• The sale prices for the common stock were significantly higher than the option exercise price, indicating a substantial profit for the reporting person.
• The company's stock price appears to be trading at a high valuation, with sales occurring between $500.52 and $510.8633 per share.

Negatives

• The CEO reduced direct beneficial ownership of common stock to 130 shares, although significant indirect ownership remains.
• Insider selling, even if planned, can sometimes be perceived negatively by the market as it reduces direct alignment with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of insider trading activity under an established plan. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an individual executive's personal financial planning.

Comparison to Industry Standards

• This is a standard Form 4 filing for an insider transaction under a 10b5-1 plan. The execution of such plans is a common practice among executives to manage personal finances while complying with insider trading regulations.
• There are no specific comparable companies, projects, or results mentioned in the filing to assess against industry benchmarks.

Related Party Transactions

• Shares are held indirectly by spouse and various family trusts (Trusts 7, 8, 9, 10), which are considered related parties.

Stakeholder Impact

• Shareholders: May view the CEO's planned selling as a normal part of executive compensation and financial planning, especially given the pre-arranged 10b5-1 plan. The high sale prices could be interpreted as the CEO capitalizing on a strong stock performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The filing states these are the final trades under the specific 10b5-1 plan entered into on May 2, 2025. No further transactions under this specific plan are expected.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan, which are generally not indicative of a fundamental shift in the company's prospects. While the CEO is selling shares, it's a planned event and not necessarily a signal of lack of confidence, especially given the significant indirect holdings. The high sale prices suggest a strong current valuation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new fundamental information to warrant a change in investment thesis, but rather confirms an executive's planned liquidity event.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Stock Sale, Beneficial Ownership